Bajaj Healthcare Limited (BHL) has announced the allotment of 20,79,409 fully convertible equity shares following the conversion of warrants issued in September 2024. The allotment, priced at ₹338 per share, was made to eight distinct allottees across Promoter and Non-Promoter Public categories. This corporate action effectively increases the company’s paid-up equity share capital from ₹15.79 Crore to ₹16.83 Crore.

The board meeting held on March 18, 2026, finalized the conversion process for warrant holders who exercised their right to receive one equity share for every warrant held. Notable participants in this conversion include Swastik Capital, which was allotted 7,82,574 shares, becoming a significant non-promoter stakeholder with a post-issue holding of 2.77%. Other individual allottees included Dr. Ashish Garg and Mr. Mohit Poddar.

Bajaj Healthcare is a leading pharmaceutical player focused on the development and manufacturing of Active Pharmaceutical Ingredients (APIs), Intermediates, and Finished Dosage Formulations. In 2025, the company expanded its portfolio by receiving CDSCO approval for Phase III clinical trials of Suvorexant Tablets. Strategic moves in early 2026 included the signing of a Deed of Assignment for the sale of a non-operational undertaking at Tarapur to Bethany Pharmacare for approximately ₹2.50 Crore.

The company’s financial performance in 2025 showed steady momentum, with the quarter ending December 2025 (Q3FY26) reporting a total income of ₹162.87 Crore and a net profit of ₹15.67 Crore. Prominent institutional investors include HDFC Mutual Fund, which holds a 1.66% stake through its Pharma and Healthcare Fund, and InCred Asset Management. The company has maintained a consistent dividend track record, declaring ₹1.00 per share in 2025.